Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Proto-oncogene tyrosine-protein kinase Src (EC 2.7.10.2) (Proto-oncogene c-Src) (pp60c-src) (p60-Src)

 SRC_RAT                 Reviewed;         536 AA.
Q9WUD9; G3V776; Q45QJ2; Q9JJ10;
30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
13-NOV-2013, sequence version 4.
30-AUG-2017, entry version 167.
RecName: Full=Proto-oncogene tyrosine-protein kinase Src;
EC=2.7.10.2;
AltName: Full=Proto-oncogene c-Src;
AltName: Full=pp60c-src;
Short=p60-Src;
Name=Src;
Rattus norvegicus (Rat).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha;
Muroidea; Muridae; Murinae; Rattus.
NCBI_TaxID=10116;
[1]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
STRAIN=Sprague-Dawley; TISSUE=Testis;
Stockand J.D., Al-Khalili O., Spier B.J., Eaton D.C.;
"Rattus norvegicus proto-oncogene encoding tyrosine-protein kinase
pp60-c-src.";
Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
[2]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND
INDUCTION.
STRAIN=Wistar; TISSUE=Temporal cortex;
PubMed=11249956; DOI=10.1016/S0028-3908(00)00185-4;
Linden A., Storvik M., Lakso M., Haapasalo A., Lee D., Witkin J.M.,
Sei Y., Castren E., Wong G.;
"Increased expression of neuronal Src and tyrosine phosphorylation of
NMDA receptors in rat brain after systemic treatment with MK-801.";
Neuropharmacology 40:469-481(2001).
[3]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
STRAIN=Brown Norway;
PubMed=15057822; DOI=10.1038/nature02426;
Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T.,
Smith D., Lee H.-M., Gustafson E., Cahill P., Kana A.,
Doucette-Stamm L., Weinstock K., Fechtel K., Weiss R.B., Dunn D.M.,
Green E.D., Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K.,
Zhu B., Marra M., Schein J., Bosdet I., Fjell C., Jones S.,
Krzywinski M., Mathewson C., Siddiqui A., Wye N., McPherson J.,
Zhao S., Fraser C.M., Shetty J., Shatsman S., Geer K., Chen Y.,
Abramzon S., Nierman W.C., Havlak P.H., Chen R., Durbin K.J., Egan A.,
Ren Y., Song X.-Z., Li B., Liu Y., Qin X., Cawley S., Cooney A.J.,
D'Souza L.M., Martin K., Wu J.Q., Gonzalez-Garay M.L., Jackson A.R.,
Kalafus K.J., McLeod M.P., Milosavljevic A., Virk D., Volkov A.,
Wheeler D.A., Zhang Z., Bailey J.A., Eichler E.E., Tuzun E.,
Birney E., Mongin E., Ureta-Vidal A., Woodwark C., Zdobnov E.,
Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D.,
Schmidt J., Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M.,
Abril J.F., Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O.,
Poliakov A., Huebner N., Ganten D., Goesele C., Hummel O.,
Kreitler T., Lee Y.-A., Monti J., Schulz H., Zimdahl H.,
Himmelbauer H., Lehrach H., Jacob H.J., Bromberg S.,
Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E., Lazar J.,
Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E.,
Webber C., Brandt P., Nyakatura G., Adetobi M., Chiaromonte F.,
Elnitski L., Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K.,
Miller W., Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S.,
Zhang Y., Lindpaintner K., Andrews T.D., Caccamo M., Clamp M.,
Clarke L., Curwen V., Durbin R.M., Eyras E., Searle S.M., Cooper G.M.,
Batzoglou S., Brudno M., Sidow A., Stone E.A., Payseur B.A.,
Bourque G., Lopez-Otin C., Puente X.S., Chakrabarti K., Chatterji S.,
Dewey C., Pachter L., Bray N., Yap V.B., Caspi A., Tesler G.,
Pevzner P.A., Haussler D., Roskin K.M., Baertsch R., Clawson H.,
Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J., Rosenbloom K.R.,
Trumbower H., Weirauch M., Cooper D.N., Stenson P.D., Ma B., Brent M.,
Arumugam M., Shteynberg D., Copley R.R., Taylor M.S., Riethman H.,
Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S., Mockrin S.,
Collins F.S.;
"Genome sequence of the Brown Norway rat yields insights into
mammalian evolution.";
Nature 428:493-521(2004).
[4]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
[5]
NUCLEOTIDE SEQUENCE [MRNA] OF 7-529 (ISOFORM 1).
STRAIN=SHR, and Wistar Kyoto;
Jackson E.K., Zhu C.;
"Genetic similarity between spontaneously hypertensive rats and
Wistar-Kyoto rats in the coding regions of signal transduction
proteins.";
Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
[6]
INTERACTION WITH PTK2B/PYK2, ENZYME REGULATION, AND PHOSPHORYLATION AT
TYR-419.
PubMed=8849729; DOI=10.1038/383547a0;
Dikic I., Tokiwa G., Lev S., Courtneidge S.A., Schlessinger J.;
"A role for Pyk2 and Src in linking G-protein-coupled receptors with
MAP kinase activation.";
Nature 383:547-550(1996).
[7]
INTERACTION WITH ARRB1.
PubMed=10995467; DOI=10.1073/pnas.190276697;
DeFea K.A., Vaughn Z.D., O'Bryan E.M., Nishijima D., Dery O.,
Bunnett N.W.;
"The proliferative and antiapoptotic effects of substance P are
facilitated by formation of a beta -arrestin-dependent scaffolding
complex.";
Proc. Natl. Acad. Sci. U.S.A. 97:11086-11091(2000).
[8]
INTERACTION WITH DDR2.
PubMed=11884411; DOI=10.1074/jbc.M201078200;
Ikeda K., Wang L.H., Torres R., Zhao H., Olaso E., Eng F.J.,
Labrador P., Klein R., Lovett D., Yancopoulos G.D., Friedman S.L.,
Lin H.C.;
"Discoidin domain receptor 2 interacts with Src and Shc following its
activation by type I collagen.";
J. Biol. Chem. 277:19206-19212(2002).
[9]
INTERACTION WITH DAB2.
PubMed=12473651; DOI=10.1074/jbc.M210628200;
Zhou J., Scholes J., Hsieh J.T.;
"Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src
in normal prostatic epithelium and cancer.";
J. Biol. Chem. 278:6936-6941(2003).
[10]
FUNCTION, AND INTERACTION WITH DDR2.
PubMed=16186108; DOI=10.1074/jbc.M506921200;
Yang K., Kim J.H., Kim H.J., Park I.S., Kim I.Y., Yang B.S.;
"Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src
stimulates intramolecular autophosphorylation and Shc signaling
complex formation.";
J. Biol. Chem. 280:39058-39066(2005).
[11]
INTERACTION WITH CEACAM1.
PubMed=19948503; DOI=10.1083/jcb.200904150;
Mueller M.M., Klaile E., Vorontsova O., Singer B.B., Obrink B.;
"Homophilic adhesion and CEACAM1-S regulate dimerization of CEACAM1-L
and recruitment of SHP-2 and c-Src.";
J. Cell Biol. 187:569-581(2009).
[12]
PHOSPHORYLATION AT TYR-530, AND DEPHOSPHORYLATION AT TYR-530 BY PTPRJ.
PubMed=15735685; DOI=10.1038/sj.onc.1208510;
Pera I.L., Iuliano R., Florio T., Susini C., Trapasso F., Santoro M.,
Chiariotti L., Schettini G., Viglietto G., Fusco A.;
"The rat tyrosine phosphatase eta increases cell adhesion by
activating c-Src through dephosphorylation of its inhibitory
phosphotyrosine residue.";
Oncogene 24:3187-3195(2005).
[13]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17, AND IDENTIFICATION
BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=22673903; DOI=10.1038/ncomms1871;
Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A.,
Lundby C., Olsen J.V.;
"Quantitative maps of protein phosphorylation sites across 14
different rat organs and tissues.";
Nat. Commun. 3:876-876(2012).
-!- FUNCTION: Non-receptor protein tyrosine kinase which is activated
following engagement of many different classes of cellular
receptors including immune response receptors, integrins and other
adhesion receptors, receptor protein tyrosine kinases, G protein-
coupled receptors as well as cytokine receptors. Participates in
signaling pathways that control a diverse spectrum of biological
activities including gene transcription, immune response, cell
adhesion, cell cycle progression, apoptosis, migration, and
transformation. Due to functional redundancy between members of
the SRC kinase family, identification of the specific role of each
SRC kinase is very difficult. SRC appears to be one of the primary
kinases activated following engagement of receptors and plays a
role in the activation of other protein tyrosine kinase (PTK)
families. Receptor clustering or dimerization leads to recruitment
of SRC to the receptor complexes where it phosphorylates the
tyrosine residues within the receptor cytoplasmic domains. Plays
an important role in the regulation of cytoskeletal organization
through phosphorylation of specific substrates such as AFAP1.
Phosphorylation of AFAP1 allows the SRC SH2 domain to bind AFAP1
and to localize to actin filaments. Cytoskeletal reorganization is
also controlled through the phosphorylation of cortactin (CTTN).
When cells adhere via focal adhesions to the extracellular matrix,
signals are transmitted by integrins into the cell resulting in
tyrosine phosphorylation of a number of focal adhesion proteins,
including PTK2/FAK1 and paxillin (PXN). In addition to
phosphorylating focal adhesion proteins, SRC is also active at the
sites of cell-cell contact adherens junctions and phosphorylates
substrates such as beta-catenin (CTNNB1), delta-catenin (CTNND1),
and plakoglobin (JUP). Another type of cell-cell junction, the gap
junction, is also a target for SRC, which phosphorylates connexin-
43 (GJA1). SRC is implicated in regulation of pre-mRNA-processing
and phosphorylates RNA-binding proteins such as KHDRBS1. Also
plays a role in PDGF-mediated tyrosine phosphorylation of both
STAT1 and STAT3, leading to increased DNA binding activity of
these transcription factors. Involved in the RAS pathway through
phosphorylation of RASA1 and RASGRF1. Plays a role in EGF-mediated
calcium-activated chloride channel activation. Required for
epidermal growth factor receptor (EGFR) internalization through
phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr-
1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization
through phosphorylation and activation of GRK2, leading to beta-
arrestin phosphorylation and internalization. Has a critical role
in the stimulation of the CDK20/MAPK3 mitogen-activated protein
kinase cascade by epidermal growth factor. Might be involved not
only in mediating the transduction of mitogenic signals at the
level of the plasma membrane but also in controlling progression
through the cell cycle via interaction with regulatory proteins in
the nucleus. Plays an important role in osteoclastic bone
resorption in conjunction with PTK2B/PYK2. Both the formation of a
SRC-PTK2B/PYK2 complex and SRC kinase activity are necessary for
this function. Recruited to activated integrins by PTK2B/PYK2,
thereby phosphorylating CBL, which in turn induces the activation
and recruitment of phosphatidylinositol 3-kinase to the cell
membrane in a signaling pathway that is critical for osteoclast
function. Promotes energy production in osteoclasts by activating
mitochondrial cytochrome C oxidase. Phosphorylates DDR2 on
tyrosine residues, thereby promoting its subsequent
autophosphorylation. Phosphorylates RUNX3 and COX2 on tyrosine
residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-738'. Enhances
DDX58/RIG-I-elicited antiviral signaling (By similarity).
Phosphorylates PDPK1 at 'Tyr-9', 'Tyr-373' and 'Tyr-376'.
Phosphorylates BCAR1 at 'Tyr-226'. Phosphorylates CBLC at multiple
tyrosine residues, phosphorylation at 'Tyr-341' activates CBLC E3
activity. Required for podosome formation (By similarity).
{ECO:0000250|UniProtKB:P05480, ECO:0000250|UniProtKB:P12931,
ECO:0000269|PubMed:16186108}.
-!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
[protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
ProRule:PRU10028}.
-!- ENZYME REGULATION: Phosphorylation by CSK at Tyr-530 inhibits
kinase activity. Inhibitory phosphorylation at Tyr-530 is enhanced
by heme. Further phosphorylation by CDK1 partially reactivates
CSK-inactivated SRC and facilitates complete reactivation by
protein tyrosine phosphatase PTPRC. Integrin engagement stimulates
kinase activity. Phosphorylation by PTK2/FAK1 enhances kinase
activity. Butein and pseudosubstrate-based peptide inhibitors like
CIYKYYF act as inhibitors (By similarity). Phosphorylation at Tyr-
419 increases kinase activity. {ECO:0000250,
ECO:0000269|PubMed:8849729}.
-!- SUBUNIT: Interacts with DDEF1/ASAP1; via the SH3 domain. Interacts
with CCPG1. Identified in a complex containing FGFR4, NCAM1, CDH2,
PLCG1, FRS2, SRC, SHC1, GAP43 and CTTN. Interacts with ERBB2,
STAT1 and PNN. Interacts with CDCP1, PELP1, TGFB1I1 and TOM1L2.
Interacts with the cytoplasmic domain of MUC1, phosphorylates it
and increases binding of MUC1 with beta-catenin. Interacts with
RALGPS1; via the SH3 domain. Interacts with HEV ORF3 protein; via
the SH3 domain. Interacts with CAV2 (tyrosine phosphorylated
form). Interacts (via the SH3 domain and the protein kinase
domain) with ARRB1; the interaction is independent of the
phosphorylation state of SRC C-terminus. Interacts with ARRB1 and
ARRB2. Interacts with SRCIN1. Interacts with NDFIP2 and more
weakly with NDFIP1. Interacts with PIK3CA and/or PIK3C2B,
PTK2/FAK1 and ESR1 (dimethylated on arginine). Interacts with
FASLG. Interacts (via SH2 domain) with the 'Tyr-402'
phosphorylated form of PTK2B/PYK2. Interacts (via SH2 domain) with
FLT3 (tyrosine phosphorylated). Interacts (via SH2 and SH3 domain)
with TNK2. Interacts (via protein kinase domain) with the tyrosine
phosphorylated form of RUNX3 (via runt domain). Interacts with
TRAF3 (via RING-type zinc finger domain). Interacts with DDX58,
MAVS and TBK1. Interacts (via SH2 domain) with RACK1; the
interaction is enhanced by tyrosine phosphorylation of RACK1 and
inhibits SRC activity. Interacts with EPHB1; activates the
MAPK/ERK cascade to regulate cell migration. Interacts with FCAMR.
Interacts with PDGFRA (tyrosine phosphorylated). Interacts with
CSF1R. Interacts with DDR1. Interacts (via SH2 domain) with the
'Tyr-9' phosphorylated form of PDPK1. Interacts with AMOTL2; this
interaction promotes the translocation of phosphorylated SRC to
peripheral cell-matrix adhesion sites. Interacts with DDR2 and
DAB2. Interacts with TRAP1. Interacts with CBLC; the interaction
is enhanced when SRC is phosphorylated at Tyr-419. Interacts with
ARHGEF5 (By similarity). Interacts (via cytoplasmic domain) with
CEACAM1 (via SH2 domain); this interaction is regulated by trans-
homophilic cell adhesion (PubMed:19948503). Interacts with MPP2
(By similarity). {ECO:0000250|UniProtKB:P05480,
ECO:0000250|UniProtKB:P12931, ECO:0000269|PubMed:10995467,
ECO:0000269|PubMed:11884411, ECO:0000269|PubMed:12473651,
ECO:0000269|PubMed:16186108, ECO:0000269|PubMed:19948503,
ECO:0000269|PubMed:8849729}.
-!- INTERACTION:
P22002:Cacna1c; NbExp=4; IntAct=EBI-7784541, EBI-1185084;
P28648:Cd63; NbExp=2; IntAct=EBI-7784541, EBI-7784314;
O08617:Ptprr; NbExp=2; IntAct=EBI-7784541, EBI-8584374;
-!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}. Mitochondrion
inner membrane {ECO:0000250}. Nucleus {ECO:0000250}. Cytoplasm,
cytoskeleton {ECO:0000250}. Note=Localizes to focal adhesion sites
after integrin engagement. Localization to focal adhesion sites
requires myristoylation and the SH3 domain. {ECO:0000250}.
-!- ALTERNATIVE PRODUCTS:
Event=Alternative splicing; Named isoforms=2;
Name=1;
IsoId=Q9WUD9-1; Sequence=Displayed;
Name=2; Synonyms=Neuronal Src;
IsoId=Q9WUD9-2; Sequence=VSP_053395;
-!- TISSUE SPECIFICITY: Isoform 2 is expressed in the brain with
highest expression in the pyramidal layers of the hippocampus and
the granular layer of the dentate gyrus and moderate expression in
cortical regions, with higher levels in the superficial layers
than in the deep layers. Isoform 2 may be neuron-specific. Isoform
1 is expressed at very low levels in the forebrain.
{ECO:0000269|PubMed:11249956}.
-!- INDUCTION: Isoform 2 is up-regulated by MK-801, an uncompetitive
N-methyl-d-aspartate (NMDA) receptor antagonist, mostly in the
superficial layers of the parietal, temporal, occipital and
frontal cortices. {ECO:0000269|PubMed:11249956}.
-!- PTM: Myristoylated at Gly-2, and this is essential for targeting
to membranes. {ECO:0000250}.
-!- PTM: Dephosphorylated at Tyr-530 by PTPRJ. Phosphorylated on Tyr-
530 by c-Src kinase (CSK). The phosphorylated form is termed
pp60c-src (By similarity). Dephosphorylated by PTPRJ at Tyr-419.
Normally maintained in an inactive conformation with the SH2
domain engaged with Tyr-530, the SH3 domain engaged with the SH2-
kinase linker, and Tyr-419 dephosphorylated. Dephosphorylation of
Tyr-530 as a result of protein tyrosine phosphatase (PTP) action
disrupts the intramolecular interaction between the SH2 domain and
Tyr-530, Tyr-419 can then become autophosphorylated, resulting in
SRX activation. Phosphorylation of Tyr-530 by CSK allows this
interaction to reform, resulting in SRC inactivation. CDK5-
mediated phosphorylation at Ser-75 targets SRC to ubiquitin-
dependent degradation and thus leads to cytoskeletal
reorganization. Phosphorylated by PTK2/FAK1; this enhances kinase
activity (By similarity). Phosphorylated by PTK2B/PYK2; this
enhances kinase activity. {ECO:0000250,
ECO:0000269|PubMed:15735685, ECO:0000269|PubMed:8849729}.
-!- PTM: S-nitrosylation is important for activation of its kinase
activity. {ECO:0000250}.
-!- PTM: Ubiquitinated in response to CDK5-mediated phosphorylation.
Ubiquitination mediated by CBLC requires SRC autophosphorylation
at Tyr-419 and may lead to lysosomal degradation (By similarity).
{ECO:0000250}.
-!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
kinase family. SRC subfamily. {ECO:0000255|PROSITE-
ProRule:PRU00159}.
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; AF130457; AAD24180.1; -; mRNA.
EMBL; AF157016; AAF80335.1; -; mRNA.
EMBL; AABR06027223; -; NOT_ANNOTATED_CDS; Genomic_DNA.
EMBL; CH474005; EDL96675.1; -; Genomic_DNA.
EMBL; CH474005; EDL96676.1; -; Genomic_DNA.
EMBL; CH474005; EDL96677.1; -; Genomic_DNA.
EMBL; CH474005; EDL96678.1; -; Genomic_DNA.
EMBL; CH474005; EDL96679.1; -; Genomic_DNA.
EMBL; DQ120509; AAZ23848.1; -; mRNA.
EMBL; DQ120510; AAZ23849.1; -; mRNA.
RefSeq; NP_114183.1; NM_031977.1. [Q9WUD9-2]
RefSeq; XP_008760609.1; XM_008762387.2. [Q9WUD9-2]
RefSeq; XP_008760610.1; XM_008762388.2. [Q9WUD9-2]
RefSeq; XP_017447554.1; XM_017592065.1. [Q9WUD9-2]
RefSeq; XP_017447555.1; XM_017592066.1. [Q9WUD9-2]
RefSeq; XP_017447556.1; XM_017592067.1. [Q9WUD9-2]
RefSeq; XP_017447557.1; XM_017592068.1. [Q9WUD9-2]
RefSeq; XP_017447558.1; XM_017592069.1. [Q9WUD9-2]
RefSeq; XP_017447559.1; XM_017592070.1. [Q9WUD9-2]
RefSeq; XP_017447560.1; XM_017592071.1. [Q9WUD9-2]
RefSeq; XP_017447561.1; XM_017592072.1. [Q9WUD9-1]
UniGene; Rn.112600; -.
SMR; Q9WUD9; -.
BioGrid; 249840; 11.
DIP; DIP-42731N; -.
ELM; Q9WUD9; -.
IntAct; Q9WUD9; 8.
MINT; MINT-1488989; -.
STRING; 10116.ENSRNOP00000012739; -.
BindingDB; Q9WUD9; -.
ChEMBL; CHEMBL3014; -.
iPTMnet; Q9WUD9; -.
PhosphoSitePlus; Q9WUD9; -.
PaxDb; Q9WUD9; -.
PeptideAtlas; Q9WUD9; -.
PRIDE; Q9WUD9; -.
Ensembl; ENSRNOT00000012739; ENSRNOP00000012739; ENSRNOG00000009495. [Q9WUD9-1]
Ensembl; ENSRNOT00000080516; ENSRNOP00000071837; ENSRNOG00000009495. [Q9WUD9-2]
GeneID; 83805; -.
KEGG; rno:83805; -.
UCSC; RGD:620795; rat. [Q9WUD9-1]
CTD; 6714; -.
RGD; 620795; Src.
eggNOG; KOG0197; Eukaryota.
eggNOG; COG0515; LUCA.
GeneTree; ENSGT00760000118938; -.
HOGENOM; HOG000233858; -.
HOVERGEN; HBG008761; -.
InParanoid; Q9WUD9; -.
KO; K05704; -.
OMA; CQCWRKD; -.
TreeFam; TF351634; -.
BRENDA; 2.7.10.2; 5301.
Reactome; R-RNO-1227986; Signaling by ERBB2.
Reactome; R-RNO-1295596; Spry regulation of FGF signaling.
Reactome; R-RNO-1433557; Signaling by SCF-KIT.
Reactome; R-RNO-1433559; Regulation of KIT signaling.
Reactome; R-RNO-177929; Signaling by EGFR.
Reactome; R-RNO-180292; GAB1 signalosome.
Reactome; R-RNO-186763; Downstream signal transduction.
Reactome; R-RNO-191647; c-src mediated regulation of Cx43 function and closure of gap junctions.
Reactome; R-RNO-2029481; FCGR activation.
Reactome; R-RNO-354192; Integrin alphaIIb beta3 signaling.
Reactome; R-RNO-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
Reactome; R-RNO-372708; p130Cas linkage to MAPK signaling for integrins.
Reactome; R-RNO-389356; CD28 co-stimulation.
Reactome; R-RNO-389513; CTLA4 inhibitory signaling.
Reactome; R-RNO-391160; Signal regulatory protein (SIRP) family interactions.
Reactome; R-RNO-3928662; EPHB-mediated forward signaling.
Reactome; R-RNO-3928663; EPHA-mediated growth cone collapse.
Reactome; R-RNO-3928664; Ephrin signaling.
Reactome; R-RNO-3928665; EPH-ephrin mediated repulsion of cells.
Reactome; R-RNO-418592; ADP signalling through P2Y purinoceptor 1.
Reactome; R-RNO-418885; DCC mediated attractive signaling.
Reactome; R-RNO-430116; GP1b-IX-V activation signalling.
Reactome; R-RNO-437239; Recycling pathway of L1.
Reactome; R-RNO-4420097; VEGFA-VEGFR2 Pathway.
Reactome; R-RNO-456926; Thrombin signalling through proteinase activated receptors (PARs).
Reactome; R-RNO-5218921; VEGFR2 mediated cell proliferation.
Reactome; R-RNO-5607764; CLEC7A (Dectin-1) signaling.
Reactome; R-RNO-5663220; RHO GTPases Activate Formins.
Reactome; R-RNO-5673000; RAF activation.
Reactome; R-RNO-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
Reactome; R-RNO-69231; Cyclin D associated events in G1.
Reactome; R-RNO-8853659; RET signaling.
Reactome; R-RNO-8874081; MET activates PTK2 signaling.
Reactome; R-RNO-8934903; Receptor Mediated Mitophagy.
Reactome; R-RNO-8941858; Regulation of RUNX3 expression and activity.
PRO; PR:Q9WUD9; -.
Proteomes; UP000002494; Chromosome 3.
Bgee; ENSRNOG00000009495; -.
Genevisible; Q9WUD9; RN.
GO; GO:0005884; C:actin filament; IEA:Ensembl.
GO; GO:0005901; C:caveola; IDA:RGD.
GO; GO:0005829; C:cytosol; TAS:Reactome.
GO; GO:0070062; C:extracellular exosome; IEA:Ensembl.
GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
GO; GO:0005770; C:late endosome; IEA:Ensembl.
GO; GO:0005764; C:lysosome; IEA:Ensembl.
GO; GO:0005743; C:mitochondrial inner membrane; ISS:UniProtKB.
GO; GO:0043005; C:neuron projection; IDA:RGD.
GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
GO; GO:0005886; C:plasma membrane; IDA:RGD.
GO; GO:0002102; C:podosome; IEA:Ensembl.
GO; GO:0014069; C:postsynaptic density; IDA:RGD.
GO; GO:0032587; C:ruffle membrane; IEA:Ensembl.
GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
GO; GO:0045296; F:cadherin binding; IEA:Ensembl.
GO; GO:0050839; F:cell adhesion molecule binding; IPI:RGD.
GO; GO:0071253; F:connexin binding; IEA:Ensembl.
GO; GO:0019899; F:enzyme binding; IPI:RGD.
GO; GO:0046875; F:ephrin receptor binding; IEA:Ensembl.
GO; GO:0030331; F:estrogen receptor binding; IPI:RGD.
GO; GO:0070851; F:growth factor receptor binding; IBA:GO_Central.
GO; GO:0020037; F:heme binding; ISS:UniProtKB.
GO; GO:0005158; F:insulin receptor binding; IPI:RGD.
GO; GO:0044325; F:ion channel binding; IPI:RGD.
GO; GO:0016301; F:kinase activity; TAS:RGD.
GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central.
GO; GO:0051219; F:phosphoprotein binding; IEA:Ensembl.
GO; GO:0008022; F:protein C-terminus binding; IPI:RGD.
GO; GO:0032403; F:protein complex binding; IPI:RGD.
GO; GO:0019901; F:protein kinase binding; IPI:RGD.
GO; GO:0005080; F:protein kinase C binding; IPI:RGD.
GO; GO:0004713; F:protein tyrosine kinase activity; IDA:RGD.
GO; GO:0005102; F:receptor binding; IPI:RGD.
GO; GO:0097110; F:scaffold protein binding; IEA:Ensembl.
GO; GO:0042169; F:SH2 domain binding; IEA:Ensembl.
GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:RGD.
GO; GO:0032148; P:activation of protein kinase B activity; IMP:UniProtKB.
GO; GO:0034332; P:adherens junction organization; IDA:RGD.
GO; GO:0086098; P:angiotensin-activated signaling pathway involved in heart process; IEA:Ensembl.
GO; GO:0045453; P:bone resorption; ISS:UniProtKB.
GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
GO; GO:0016477; P:cell migration; IEA:Ensembl.
GO; GO:0008283; P:cell proliferation; IDA:RGD.
GO; GO:0071398; P:cellular response to fatty acid; IEP:RGD.
GO; GO:0071498; P:cellular response to fluid shear stress; IEA:Ensembl.
GO; GO:0071456; P:cellular response to hypoxia; IEP:RGD.
GO; GO:0032869; P:cellular response to insulin stimulus; IEP:RGD.
GO; GO:0071222; P:cellular response to lipopolysaccharide; IEP:RGD.
GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl.
GO; GO:0071393; P:cellular response to progesterone stimulus; IMP:BHF-UCL.
GO; GO:0034614; P:cellular response to reactive oxygen species; IEA:Ensembl.
GO; GO:0007417; P:central nervous system development; IBA:GO_Central.
GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IEP:RGD.
GO; GO:0030900; P:forebrain development; IEA:Ensembl.
GO; GO:0045087; P:innate immune response; IBA:GO_Central.
GO; GO:0007229; P:integrin-mediated signaling pathway; IEA:Ensembl.
GO; GO:0030520; P:intracellular estrogen receptor signaling pathway; IBA:GO_Central.
GO; GO:0035556; P:intracellular signal transduction; IEA:Ensembl.
GO; GO:2000811; P:negative regulation of anoikis; IEA:Ensembl.
GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IBA:GO_Central.
GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:BHF-UCL.
GO; GO:2001243; P:negative regulation of intrinsic apoptotic signaling pathway; IBA:GO_Central.
GO; GO:0051902; P:negative regulation of mitochondrial depolarization; IEA:Ensembl.
GO; GO:0032463; P:negative regulation of protein homooligomerization; IEA:Ensembl.
GO; GO:0051974; P:negative regulation of telomerase activity; IEA:Ensembl.
GO; GO:0032211; P:negative regulation of telomere maintenance via telomerase; IEA:Ensembl.
GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:UniProtKB.
GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IDA:RGD.
GO; GO:0048477; P:oogenesis; IEA:Ensembl.
GO; GO:0036035; P:osteoclast development; IBA:GO_Central.
GO; GO:0018105; P:peptidyl-serine phosphorylation; IMP:UniProtKB.
GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
GO; GO:0043065; P:positive regulation of apoptotic process; IDA:RGD.
GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IEA:Ensembl.
GO; GO:0045785; P:positive regulation of cell adhesion; IDA:RGD.
GO; GO:0045737; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity; IMP:UniProtKB.
GO; GO:0050715; P:positive regulation of cytokine secretion; IMP:RGD.
GO; GO:2000573; P:positive regulation of DNA biosynthetic process; IMP:UniProtKB.
GO; GO:0010634; P:positive regulation of epithelial cell migration; IEA:Ensembl.
GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
GO; GO:0010628; P:positive regulation of gene expression; IMP:RGD.
GO; GO:0010907; P:positive regulation of glucose metabolic process; IMP:RGD.
GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; IDA:RGD.
GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:RGD.
GO; GO:2000394; P:positive regulation of lamellipodium morphogenesis; IEA:Ensembl.
GO; GO:0043406; P:positive regulation of MAP kinase activity; IMP:UniProtKB.
GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IMP:UniProtKB.
GO; GO:0010641; P:positive regulation of platelet-derived growth factor receptor signaling pathway; IEP:UniProtKB.
GO; GO:0071803; P:positive regulation of podosome assembly; IEA:Ensembl.
GO; GO:0031954; P:positive regulation of protein autophosphorylation; IMP:UniProtKB.
GO; GO:0051897; P:positive regulation of protein kinase B signaling; IEA:Ensembl.
GO; GO:1900182; P:positive regulation of protein localization to nucleus; IEA:Ensembl.
GO; GO:0010954; P:positive regulation of protein processing; IEA:Ensembl.
GO; GO:0051222; P:positive regulation of protein transport; IMP:RGD.
GO; GO:0051057; P:positive regulation of small GTPase mediated signal transduction; IEA:Ensembl.
GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IMP:RGD.
GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:UniProtKB.
GO; GO:0050847; P:progesterone receptor signaling pathway; IMP:BHF-UCL.
GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
GO; GO:0031648; P:protein destabilization; IEA:Ensembl.
GO; GO:2001286; P:regulation of caveolin-mediated endocytosis; IEA:Ensembl.
GO; GO:0060491; P:regulation of cell projection assembly; IEA:Ensembl.
GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
GO; GO:0022407; P:regulation of cell-cell adhesion; IEA:Ensembl.
GO; GO:2000641; P:regulation of early endosome to late endosome transport; IEA:Ensembl.
GO; GO:0033146; P:regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl.
GO; GO:0071801; P:regulation of podosome assembly; IBA:GO_Central.
GO; GO:0043393; P:regulation of protein binding; IEA:Ensembl.
GO; GO:0010447; P:response to acidic pH; IEP:RGD.
GO; GO:0042493; P:response to drug; IEP:RGD.
GO; GO:0051602; P:response to electrical stimulus; IEP:RGD.
GO; GO:0070542; P:response to fatty acid; IEP:RGD.
GO; GO:0042542; P:response to hydrogen peroxide; IEP:RGD.
GO; GO:0070555; P:response to interleukin-1; IEA:Ensembl.
GO; GO:0009612; P:response to mechanical stimulus; IEP:RGD.
GO; GO:0051385; P:response to mineralocorticoid; IEP:RGD.
GO; GO:0031667; P:response to nutrient levels; IEP:RGD.
GO; GO:0009615; P:response to virus; IEP:RGD.
GO; GO:0016337; P:single organismal cell-cell adhesion; IEP:RGD.
GO; GO:0043149; P:stress fiber assembly; IEA:Ensembl.
GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl.
GO; GO:0045056; P:transcytosis; IDA:RGD.
GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
GO; GO:0060065; P:uterus development; IEA:Ensembl.
Gene3D; 3.30.505.10; -; 1.
InterPro; IPR011009; Kinase-like_dom.
InterPro; IPR000719; Prot_kinase_dom.
InterPro; IPR017441; Protein_kinase_ATP_BS.
InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
InterPro; IPR000980; SH2.
InterPro; IPR001452; SH3_domain.
InterPro; IPR008266; Tyr_kinase_AS.
InterPro; IPR020635; Tyr_kinase_cat_dom.
Pfam; PF07714; Pkinase_Tyr; 1.
Pfam; PF00017; SH2; 1.
Pfam; PF00018; SH3_1; 1.
PRINTS; PR00401; SH2DOMAIN.
PRINTS; PR00452; SH3DOMAIN.
PRINTS; PR00109; TYRKINASE.
SMART; SM00252; SH2; 1.
SMART; SM00326; SH3; 1.
SMART; SM00219; TyrKc; 1.
SUPFAM; SSF50044; SSF50044; 1.
SUPFAM; SSF55550; SSF55550; 1.
SUPFAM; SSF56112; SSF56112; 1.
PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PROSITE; PS50001; SH2; 1.
PROSITE; PS50002; SH3; 1.
1: Evidence at protein level;
Alternative splicing; ATP-binding; Cell adhesion; Cell cycle;
Cell membrane; Complete proteome; Cytoplasm; Cytoskeleton; Immunity;
Kinase; Lipoprotein; Membrane; Mitochondrion;
Mitochondrion inner membrane; Myristate; Nucleotide-binding; Nucleus;
Phosphoprotein; Proto-oncogene; Reference proteome; SH2 domain;
SH3 domain; Transferase; Tyrosine-protein kinase; Ubl conjugation.
INIT_MET 1 1 Removed. {ECO:0000250|UniProtKB:P12931}.
CHAIN 2 536 Proto-oncogene tyrosine-protein kinase
Src.
/FTId=PRO_0000088143.
DOMAIN 84 145 SH3. {ECO:0000255|PROSITE-
ProRule:PRU00192}.
DOMAIN 151 248 SH2. {ECO:0000255|PROSITE-
ProRule:PRU00191}.
DOMAIN 270 523 Protein kinase. {ECO:0000255|PROSITE-
ProRule:PRU00159}.
NP_BIND 276 284 ATP. {ECO:0000255|PROSITE-
ProRule:PRU00159}.
ACT_SITE 389 389 Proton acceptor. {ECO:0000255|PROSITE-
ProRule:PRU00159, ECO:0000255|PROSITE-
ProRule:PRU10028}.
BINDING 298 298 ATP. {ECO:0000255|PROSITE-
ProRule:PRU00159}.
MOD_RES 17 17 Phosphoserine.
{ECO:0000244|PubMed:22673903}.
MOD_RES 34 34 Phosphoserine.
{ECO:0000250|UniProtKB:P12931}.
MOD_RES 69 69 Phosphoserine.
{ECO:0000250|UniProtKB:P12931}.
MOD_RES 74 74 Phosphothreonine.
{ECO:0000250|UniProtKB:P12931}.
MOD_RES 75 75 Phosphoserine; by CDK5.
{ECO:0000250|UniProtKB:P12931}.
MOD_RES 187 187 Phosphotyrosine.
{ECO:0000250|UniProtKB:P05480}.
MOD_RES 419 419 Phosphotyrosine; by FAK2.
{ECO:0000269|PubMed:8849729}.
MOD_RES 420 420 Phosphothreonine; by autocatalysis.
{ECO:0000250}.
MOD_RES 439 439 Phosphotyrosine.
{ECO:0000250|UniProtKB:P12931}.
MOD_RES 511 511 Phosphothreonine.
{ECO:0000250|UniProtKB:P12931}.
MOD_RES 522 522 Phosphotyrosine.
{ECO:0000250|UniProtKB:P12931}.
MOD_RES 530 530 Phosphotyrosine; by CSK.
{ECO:0000250|UniProtKB:P12931}.
LIPID 2 2 N-myristoyl glycine. {ECO:0000250}.
VAR_SEQ 117 117 T -> TRKVDVR (in isoform 2).
{ECO:0000303|PubMed:11249956}.
/FTId=VSP_053395.
CONFLICT 143 143 S -> F (in Ref. 1; AAD24180 and 5;
AAZ23849/AAZ23848). {ECO:0000305}.
CONFLICT 381 381 E -> D (in Ref. 1; AAD24180 and 5;
AAZ23849/AAZ23848). {ECO:0000305}.
CONFLICT 528 528 P -> R (in Ref. 1; AAD24180 and 5;
AAZ23849/AAZ23848). {ECO:0000305}.
SEQUENCE 536 AA; 59973 MW; 453D1E904EC660A3 CRC64;
MGSNKSKPKD ASQRRRSLEP AENVHGAGGA FPASQTPSKP ASADGHRGPN AAFVPPAAAE
PKLFGGFNSS DTVTSPQRAG PLAGGVTTFV ALYDYESRTE TDLSFKKGER LQIVNNTEGD
WWLAHSLSTG QTGYIPSNYV APSDSIQAEE WYFGKITRRE SERLLLNAEN PRGTFLVRES
ETTKGAYCLS VSDFDNAKGL NVKHYKIRKL DSGGFYITSR TQFNSLQQLV AYYSKHADGL
CHRLTTVCPT SKPQTQGLAK DAWEIPRESL RLEVKLGQGC FGEVWMGTWN GTTRVAIKTL
KPGTMSPEAF LQEAQVMKKL RHEKLVQLYA VVSEEPIYIV TEYMNKGSLL DFLKGETGKY
LRLPQLVDMS AQIASGMAYV ERMNYVHRDL RAANILVGEN LVCKVADFGL ARLIEDNEYT
ARQGAKFPIK WTAPEAALYG RFTIKSDVWS FGILLTELTT KGRVPYPGMV NREVLDQVER
GYRMPCPPEC PESLHDLMCQ CWRKEPEERP TFEYLQAFLE DYFTSTEPQY QPGENL


Related products :

Catalog number Product name Quantity
EIAAB39852 Homo sapiens,Human,p60-Src,pp60c-src,Proto-oncogene c-Src,Proto-oncogene tyrosine-protein kinase Src,SRC,SRC1
EIAAB39851 Mouse,Mus musculus,Neuronal proto-oncogene tyrosine-protein kinase Src,p60-Src,pp60c-src,Proto-oncogene c-Src,Src
EIAAB39850 p60-Src,pp60c-src,Proto-oncogene c-Src,Proto-oncogene tyrosine-protein kinase Src,Rat,Rattus norvegicus,Src
EIAAB39853 Chicken,Gallus gallus,p60-Src,pp60c-src,Proto-oncogene c-Src,Proto-oncogene tyrosine-protein kinase Src,SRC
EIAAB14724 Feline sarcoma_Fujinami avian sarcoma oncogene homolog,FES,FPS,Homo sapiens,Human,p93c-fes,Proto-oncogene c-Fes,Proto-oncogene c-Fps,Tyrosine-protein kinase Fes_Fps
EIAAB35721 Homo sapiens,Human,Proto-oncogene c-Ros-1,Proto-oncogene tyrosine-protein kinase ROS,ROS1
EIAAB35722 Mouse,Mus musculus,Proto-oncogene c-Ros-1,Proto-oncogene tyrosine-protein kinase ROS,Ros1,Ros-1
EIAAB34305 Mouse,Mus musculus,Proto-oncogene c-Ret,Proto-oncogene tyrosine-protein kinase receptor Ret,Ret
EIAAB35719 Proto-oncogene c-Ros-1,Proto-oncogene tyrosine-protein kinase ROS,Rat,Rattus norvegicus,Ros1
EIAAB34304 Cadherin family member 12,CDHF12,Homo sapiens,Human,Proto-oncogene c-Ret,Proto-oncogene tyrosine-protein kinase receptor Ret,RET
E0978h ELISA ERBB2,HER2,Homo sapiens,Human,Metastatic lymph node gene 19 protein,MLN 19,MLN19,NEU,NGL,p185erbB2,Proto-oncogene c-ErbB-2,Proto-oncogene Neu,Receptor tyrosine-protein kinase erbB-2,Tyrosine kin 96T
U0978h CLIA ERBB2,HER2,Homo sapiens,Human,Metastatic lymph node gene 19 protein,MLN 19,MLN19,NEU,NGL,p185erbB2,Proto-oncogene c-ErbB-2,Proto-oncogene Neu,Receptor tyrosine-protein kinase erbB-2,Tyrosine kina 96T
E0978m ELISA Erbb2,Kiaa3023,Mouse,Mus musculus,Neu,p185erbB2,Proto-oncogene c-ErbB-2,Proto-oncogene Neu,Receptor tyrosine-protein kinase erbB-2 96T
E0978m ELISA kit Erbb2,Kiaa3023,Mouse,Mus musculus,Neu,p185erbB2,Proto-oncogene c-ErbB-2,Proto-oncogene Neu,Receptor tyrosine-protein kinase erbB-2 96T
U0978m CLIA Erbb2,Kiaa3023,Mouse,Mus musculus,Neu,p185erbB2,Proto-oncogene c-ErbB-2,Proto-oncogene Neu,Receptor tyrosine-protein kinase erbB-2 96T
EIAAB35720 Chicken,Gallus gallus,Proto-oncogene c-Ros-1,Proto-oncogene tyrosine-protein kinase ROS,ROS1
E0978h ELISA kit ERBB2,HER2,Homo sapiens,Human,Metastatic lymph node gene 19 protein,MLN 19,MLN19,NEU,NGL,p185erbB2,Proto-oncogene c-ErbB-2,Proto-oncogene Neu,Receptor tyrosine-protein kinase erbB-2,Tyrosin 96T
E0978r ELISA kit Epidermal growth factor receptor-related protein,Erbb2,Neu,p185erbB2,p185neu,Proto-oncogene c-ErbB-2,Proto-oncogene Neu,Rat,Rattus norvegicus,Receptor tyrosine-protein kinase erbB-2 96T
U0978r CLIA Epidermal growth factor receptor-related protein,Erbb2,Neu,p185erbB2,p185neu,Proto-oncogene c-ErbB-2,Proto-oncogene Neu,Rat,Rattus norvegicus,Receptor tyrosine-protein kinase erbB-2 96T
E0978r ELISA Epidermal growth factor receptor-related protein,Erbb2,Neu,p185erbB2,p185neu,Proto-oncogene c-ErbB-2,Proto-oncogene Neu,Rat,Rattus norvegicus,Receptor tyrosine-protein kinase erbB-2 96T
EIAAB25166 Mos,Mouse,Mus musculus,Oocyte maturation factor mos,Proto-oncogene c-Mos,Proto-oncogene serine_threonine-protein kinase mos
EIAAB25170 Mos,Oocyte maturation factor mos,Proto-oncogene c-Mos,Proto-oncogene serine_threonine-protein kinase mos,Rat,Rattus norvegicus
EIAAB33701 cRaf,Homo sapiens,Human,Proto-oncogene c-RAF,RAF,RAF proto-oncogene serine_threonine-protein kinase,RAF1,Raf-1
EIAAB25167 Homo sapiens,Human,MOS,Oocyte maturation factor mos,Proto-oncogene c-Mos,Proto-oncogene serine_threonine-protein kinase mos
EIAAB33699 cRaf,Proto-oncogene c-RAF,Raf,RAF proto-oncogene serine_threonine-protein kinase,Raf1,Raf-1,Rat,Rattus norvegicus


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur